Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/14/2023 | 333.21% | Benchmark | → $12 | Reiterates | Speculative Buy → Speculative Buy |
08/24/2023 | 333.21% | Benchmark | → $12 | Reiterates | Speculative Buy → Speculative Buy |
07/18/2023 | 333.21% | Benchmark | → $12 | Initiates Coverage On | → Speculative Buy |
What is the target price for Intensity Therapeutics (INTS)?
The latest price target for Intensity Therapeutics (NASDAQ: INTS) was reported by Benchmark on November 14, 2023. The analyst firm set a price target for $12.00 expecting INTS to rise to within 12 months (a possible 333.21% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Intensity Therapeutics (INTS)?
The latest analyst rating for Intensity Therapeutics (NASDAQ: INTS) was provided by Benchmark, and Intensity Therapeutics reiterated their speculative buy rating.
When is the next analyst rating going to be posted or updated for Intensity Therapeutics (INTS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intensity Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intensity Therapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating Intensity Therapeutics (INTS) correct?
While ratings are subjective and will change, the latest Intensity Therapeutics (INTS) rating was a reiterated with a price target of $0.00 to $12.00. The current price Intensity Therapeutics (INTS) is trading at is $2.77, which is within the analyst's predicted range.